Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A

By: TheNewswire.com
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics and the safety of the company’s anti-inflammatory drug candidate IHL-675A. IHL-675A is a combination cannabinoid drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ) in a fixed dose combination.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  238.66
+12.00 (5.30%)
AAPL  332.06
-6.13 (-1.81%)
AMD  482.11
+52.55 (12.23%)
BAC  61.70
+0.62 (1.02%)
GOOG  334.13
-1.63 (-0.49%)
META  530.48
-55.13 (-9.41%)
MSFT  453.36
+62.82 (16.09%)
NVDA  192.90
+2.89 (1.52%)
ORCL  125.01
+7.27 (6.17%)
TSLA  304.85
+6.53 (2.19%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.